Navigation Links
How Early Detection Of Stomach Cancer Is Being Revolutionized
Date:10/25/2013

ST. LOUIS, Oct. 25, 2013 /PRNewswire-iReach/ -- Lee Biosolutions, is a manufacturer and producer of high purity proteins announces a major scientific breakthrough. The St. Louis-based biotechnology firm recently developed a proprietary process to effectively and efficiently purify and stabilize two important gastric cancer protein biomarkers. As a result, they are producing Pepsinogen I and Pepsinogen II, critical components in serum pepsinogen tests that will revolutionize early detection of stomach and gastric cancer.

(Photo: http://photos.prnewswire.com/prnh/20131025/MN04275)

According to American Association for Cancer Research (AACR), stomach cancer is the second-leading cause of cancer-related deaths worldwide and the top cause in Eastern Asia, which comprises China, Japan, Taiwan and Korea. Studies have shown that if the disease is detected early, patients five-year survival rates increases by 90 percent. Asian and European governments have been advocating mass screenings for decades, but traditional upper endoscopy procedures are painful, invasive and expensive. Lee Biosolutions proteins Pepsinogen I and Pepsinogen II production capabilities enables international diagnostics companies to quickly manufacture serum pepsinogen tests, which are affordable and easy to administer. Lee has scaled up production to meet global market demand.

"Gastric cancer screening involves H Pylori infection detection, measurement of serum pepsinogen I and II and possibly enodoscopic examination," said Burton Lee, president of Lee Biosolutions. "The challenge to-date for diagnostic companies has been producing  tests efficiently and affordably. Recently, Lee Biosolutions research and development team cracked the code for purifying and stabilizing two very important gastric and stomach cancer protein biomarkers, Pepsinogen I and Pepsinogen II, primary components in serum pepsinogen tests. We now have the expertise, processes and manufacturing capacity to produce enough of these biomarkers to make a significant impact."

Serum pepsinogen tests for gastric cancer enable healthcare providers to identify high risk patients for further monitoring. Not only do the tests increase survival rates by 90 percent but they also decrease the cost of mass screening programs. LeeBio currently has clients in Eastern Asia and Europe that plan to produce, distribute and administer the tests.

About Lee Biosolutions, Inc.
Lee Biosolutions is an international producer of high purity human, animal and recombinant proteins, biological fluids, biochemicals, antibodies and immunoreagents. Headquartered in St. Louis and founded in 1975, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee Biosolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include human neutrophil elastase, human myeloperoxidase isoform c, alpha fetoprotein, beta 2 microglobulin, and amylase. The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee Biosolutions visit www.LeeBio.com

Media Contact: Burton Lee, Lee Biosolutions, Inc, 314-968-1091, burton@leebio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Lee Biosolutions, Inc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Study suggests: Blood test can differentiate between benign lung nodules and early stage lung cancer
2. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
3. Early Opportunities to Set the Course for Successful Global Marketing Authorization, New Life Science Webinar Hosted by Xtalks
4. KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
5. Early In Vivo Visualization of Retinoblastoma Tumors in Histologic Detail
6. Vince & Associates, Brad Vince Expands Early Phase Gastrointestinal Capabilities
7. JCI early table of contents for Aug. 15, 2013
8. JCI early table of contents for Aug. 8, 2013
9. Pearly Whites Laser Dentistry Launches Ground Breaking Cavity Prevention Program that Can Lower Decay Rates by 74%
10. RiboMed and Austrian Institute of Technology Partner on Epigenetic Tests for Early Lung Cancer Detection, Sub-typing and Drug Response
11. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , ... February 28, 2017 , ... ... most advanced manufacturing technology for use in filling injectable drug products into vials, ... Vanrx Pharmasystems SA25 robotic work-cell . CEO of Singota Solutions Alisa Wright expressed ...
(Date:2/28/2017)... Feb. 28, 2017  Phosphorus, a computational genomics ... formation of the Phosphorus Scientific Advisory Board, an ... to advise the company on the development of ... initiatives. Please visit http://phosphorus.com/about-us/ to learn ... "We,ve gathered some of the top leaders ...
(Date:2/28/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... company, today announced that its Lab Testing Division(LTD),s ... once again passed US FDA,s bioequivalence (BE) inspection ... from FDA thoroughly audited WuXi,s quality system during ... operation infrastructure, equipment, sample storage, archival system, quality ...
(Date:2/28/2017)... CA (PRWEB) , ... February 28, 2017 , ... ACEA ... the treatment of chronic diseases, has announced Dr. Roger (Feng) Luo as the new ... development experience with a number of multinational drug companies, Dr. Luo will now team ...
Breaking Biology Technology:
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
Breaking Biology News(10 mins):